In this study, we investigated whether granzyme B (GZMB) in the tumor microenvironment can be a biomarker of therapeutic response and prognosis in TNBC via the immunohistochemical staining of clinical specimens from 230 patients with primary TNBC. This evidence concerns the gene GZMB and neoplasm.